Scholars Central

EditorialPublished 20 Jun 2012

New and Emerging Strategies for the Treatment of Small Cell Lung Cancer

Authors: Gregory Gorman

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Small Cell Lung Cancer (SCLC) is a very aggressive cancer that comprises 15 to 25% of all lung cancers and has its highest occurrence in smokers. Although it is generally considered to be very responsive to chemotherapy in the limited stage, it has a high incidence of recurrence. Despite its overall response rate which has been reported to be as high as 75 to 85%, patients with extensive stage disease are often refractory to the initial treatment. The long-term survival rate for SCLC for the limited disease state is approximately 15% while the advanced stage disease is often fatal in less than 1 year. Due to the asymptomatic characteristics of SCLC it often goes undiagnosed until it has progressed into the extensive stage.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Pharmaceutical Sciences & Emerging Drugs.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Pharmaceutical Sciences & Emerging Drugs
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Gregory Gorman”